Daily non-political popular news in brief.

Virus used to create experimental HIV vaccines directly impairs the immune response

Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has emerged that some of these so-called viral vector systems may undermine the immune system and should not be used for vaccine development. Now, a new study from scientists at the Wistar Institute provides strong support for the idea that some viral-vector vaccines may cause more harm than good.

Read more »

Keywords: virus, used, create, experimental, hiv, vaccines, directly, impairs, immune, response, viru, vaccine, impair

« Previous | Next »

Similar news on "Virus used to create experimental HIV vaccines directly impairs the immune response":

1. Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine
   04-15-2007 · EurekAlert!
   Experimental vaccines to help the immune system fight tumors have rarely been designed to directly stimulate helper T cells, one of the body's most critical immune responders, because of the difficult process required to isolate and clone antigens for vaccine development. Now, a new technique may allow scientists to create a melanoma vaccine able to stimulate helper T cells. The approach may also aid in the development of other vaccines against cancers or infectious diseases.
   Similar news · Read more »
   
2. Scripps Research scientists shed new light on how antibodies fight HIV
   09-06-2007 · EurekAlert!
   Leading an international team of scientists, immunologists at the Scripps Research Institute have uncovered the first evidence that an HIV antibody is most effective when it binds not only to the virus, but also to host immune cells. The findings suggest that antibody efficiency depends on both directly neutralizing the virus and activating the host immune response.
   Similar news · Read more »
   
3. Novel vaccine concept developed by scientists at the Wistar Institute
   01-31-2008 · EurekAlert!
   A new vaccine design strategy developed by scientists at the Wistar Institute could help to develop vaccines against diseases like AIDS and cervical cancer. The secret is using a herpes simplex protein called glycoprotein D to block a receptor molecule on antigen-presenting cells. Wistar scientists showed that vaccine vectors made by fusing glycoprotein D with genes from HIV and HPV antigens increase the immune system's response to those antigens in cell cultures and mice.
   Similar news · Read more »
   
4. Chronic HIV-1 infection frequently fails to protect against superinfection
   11-15-2007 · EurekAlert!
   Natural HIV-1 infection does not always elicit a protective immune response, according to a new study published Nov. 16 in PLoS Pathogens. The team of researchers show how HIV-1 vaccines may not be as reliable against superinfection as once thought. This study suggests that immune responses found in natural HIV-1 infection may not be the best path to an effective HIV-1 vaccine.
   Similar news · Read more »
   
5. Head and neck cancer vaccine targets proteins to create immune response
   04-17-2007 · EurekAlert!
   Researchers at the University of Pittsburgh Cancer Institute, in collaboration with the Gunma University School of Medicine in Japan, have developed a vaccine strategy for head and neck cancer that targets multiple peptides to activate the immune system to attack tumors. Their findings will be included in a press briefing on cancer vaccines at the annual meeting of the American Association for Cancer Research, April 14-18, at the Los Angeles Convention Center.
   Similar news · Read more »
   
6. New target for HIV/AIDS drugs and vaccine discovered
   07-26-2007 · EurekAlert!
   Researchers from Rome, Italy, describe a finding in the August 2007 print issue of the FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection. In this report, researchers demonstrate for the first time how the HIV-1 Nef viral protein delivers a one-two punch to the body's innate immune system.
   Similar news · Read more »
   
7. Immune cell communication key to hunting viruses, Jefferson immunologists show
   10-25-2006 · EurekAlert!
   Immunologists have used nanotechnology to create a novel "biosensor" to solve in part a perplexing problem in immunology: how the immune system's killer T-cells hunt down invading viruses. They have found that surprisingly little virus can turn on killer T-cells, thanks to some complicated communication among "antigen presenting" proteins that recognize and attach to the virus, making it visible to the immune system. Presenting proteins cooperate, spreading a signal among receptors and boosting T-cell response.
   Similar news · Read more »
   
8. Protecting HIV patients from Hepatitis B virus
   07-17-2007 · EurekAlert!
   As it is not quite clear how HIV patients that don’t respond to the HBV vaccine should be managed, new research from the University of Alberta has evaluated the immune response of HBV vaccine given intradermally (into the skin) in HIV-infected individuals who failed to respond to two cycles of HBV vaccine given intramuscularly (into the muscle).
   Similar news · Read more »
   
9. Novel genetics research advances possibility of HIV vaccine
   07-05-2007 · EurekAlert!
   A pioneering collaborative study has discovered how the HIV virus evades the human body's immune system. The research collaborative -- involving scientists from the British Columbia Centre for Excellence in HIV/AIDS, Massachusetts General Hospital, Microsoft Research and Los Alamos National Laboratory -- used highly computer-intensive, cutting-edge statistical research methods to investigate how the HIV virus mutates to escape the body's immune system.
   Similar news · Read more »
   
10. Handicapping tuberculosis may be the way to a better vaccine
    08-01-2007 · EurekAlert!
    Howard Hughes Medical Institute investigator William R. Jacobs and colleagues have produced a genetically altered strain of tuberculosis, that elicits a stronger immune response than the current vaccine, bacillus Calmette-Guйrin. The new vaccine improves survival of infected animals and may help put scientists on track to replace BCG, which has been used for nearly a century although it is largely ineffective.
    Similar news · Read more »